Eton Pharmaceuticals, Inc. ETON
Nov 10, 2026, 9:54 AM EST
- YTD
- +288.23%
- 1 year
- +288.00%
- Market cap
- 1.89B
- Revenue (ttm)
- 141.06M
- Profit margin
- 35.35%
- EPS (ttm)
- 1.54
- Shares out
- 28.84M
- P/E ratio
- 42.63
- Forward P/E
- 19.47
- YTD return
- +288.23%
- 1-year return
- +288.00%
- Volume
- 146.10K
- Avg volume
- 594.19K
- Open
- 63.63
- Previous close
- 64.35
- Day's range
- 63.63 – 66.20
- 52-week range
- 14.27 – 66.37
- Beta
- 0.83
- Analysts
- Strong Buy
- Price target
- 78.00 (+18.8%)
- Earnings date
- Mar 18, 2027
5D +13.18 (+25.76%)
Key statistics
- Enterprise value
- 1.60B
- PEG ratio
- 0.00
- Price / sales
- 13.16
- Price / book
- 21.35
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 157.90%
- Free cash flow
- 13.96M
- Total cash
- 55.63M
- Total debt
- 24.33M
- Return on equity
- 90.62%
- Short % of float
- 9.29%
- 50-day average
- 54.80
- 200-day average
- 36.61
Analyst view
Consensus: strong buy
- Target (low)
- 70.00
- Target (mean)
- 78.00
- Target (high)
- 82.00
- Strong buy0
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 18, 2027
Expected Mar 18, 2027. Consensus EPS estimate 0.68.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 18, 2027 | Mar 30, 2027 | 0.38 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | 0.3125 | 0.50 | +0.19 | +60.00% |
| Aug 13, 2026 | Jun 30, 2026 | 0.1898 | 0.35 | +0.16 | +84.40% |
| May 14, 2026 | Mar 31, 2026 | 0.10 | 0.05 | -0.05 | -50.00% |
| Mar 19, 2026 | Dec 31, 2025 | 0.12 | 0.05 | -0.07 | -58.33% |
| Nov 6, 2025 | Sep 30, 2025 | 0.16 | -0.07 | -0.23 | -143.75% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2026 | Canaccord Genuity | main | Buy | Buy |
| Nov 6, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Oct 14, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 14, 2026 | Canaccord Genuity | main | Buy | Buy |
| Aug 14, 2026 | B. Riley Securities | reit | Buy | Buy |
| Aug 14, 2026 | HC Wainwright & Co. | main | Buy | Buy |
About Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- etonpharma.com
News
Canaccord Genuity Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $80 - HC Wainwright & Co. Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $80
12 Health Care Stocks Moving In Friday's Pre-Market Session 
Eton Q3 Earnings Call Highlights Growth and Pipeline Expansion 
Why Cloudflare Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket 
Eton Pharmaceuticals Q3 Earnings Call Highlights 
Eton Pharmaceuticals Q3 2026 Earnings Call Transcript 
Eton Pharmaceuticals Announces Its ET-700 Zing Acetate Formulation Shows Lower Rate Of Drug Related Adverse Events In Pilot Trial Than GALZIN; No Serious Adverse Events Seen 
Eton Pharmaceuticals to Present at 2026 Jefferies Global Healthcare Conference in London 
Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Your note
Sign in to keep a note on ETON — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADAMS JENNIFER MCKIE | Director | Conversion of Exercise of derivative security | Jun 16, 2026 | 0 |
| BRYNJELSEN SEAN E | Chief Executive Officer | Sale | Aug 19, 2026 | 961,194 |
| GRUBER JAMES R | Chief Financial Officer | Sale | Aug 19, 2025 | 204,753 |
| KREMPA DAVID | Officer | Sale | Oct 5, 2026 | 43,381 |
| MAIER PAUL V | Director | Conversion of Exercise of derivative security | Aug 27, 2026 | 59,745 |
| OPALEYE MANAGEMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | Sale | Jul 13, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Opaleye Management Inc. | 9.92% | 2,860,000 | 184.07M | Jun 29, 2026 |
| EcoR1 Capital, LLC | 7.53% | 2,171,938 | 139.79M | Jun 29, 2026 |
| Blackrock Inc. | 6.57% | 1,895,833 | 122.02M | Jun 29, 2026 |
| Nantahala Capital Management, LLC | 4.08% | 1,175,951 | 75.68M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.39% | 976,570 | 62.85M | Jun 29, 2026 |
| Morgan Stanley | 2.66% | 767,972 | 49.43M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Russell 2000 ETF | 2.40% | 690,942 | 44.47M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.37% | 684,821 | 44.08M | Jun 29, 2026 |
| OBERWEIS FUNDS-Oberweis Micro-Cap Fund | 1.68% | 483,900 | 31.14M | Jun 29, 2026 |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 1.52% | 439,150 | 28.26M | Aug 30, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.01% | 292,342 | 18.82M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.94% | 271,079 | 17.45M | Jun 29, 2026 |